메뉴 건너뛰기




Volumn 168, Issue 5, 2013, Pages 923-924

Anti-tumour necrosis factor-α treatment and weight gain in psoriasis: The 'pudgy blanching' conundrum

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

EID: 84876964357     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12284     Document Type: Editorial
Times cited : (2)

References (22)
  • 1
    • 84876967879 scopus 로고    scopus 로고
    • Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: A prospective cohort study
    • Gisondi P, Conti A, Galdo G, et al. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol 2013; 168: 1124-7.
    • (2013) Br J Dermatol , vol.168 , pp. 1124-1127
    • Gisondi, P.1    Conti, A.2    Galdo, G.3
  • 2
    • 39049173409 scopus 로고    scopus 로고
    • Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: A retrospective cohort study
    • Gisondi P, Cotena C, Tessari G, Girolomoni G,. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22: 341-4.
    • (2008) J Eur Acad Dermatol Venereol , vol.22 , pp. 341-344
    • Gisondi, P.1    Cotena, C.2    Tessari, G.3    Girolomoni, G.4
  • 3
    • 42749094559 scopus 로고    scopus 로고
    • Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis
    • Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57: 290-5.
    • (2008) Pharmacol Res , vol.57 , pp. 290-295
    • Saraceno, R.1    Schipani, C.2    Mazzotta, A.3
  • 4
    • 62649136592 scopus 로고    scopus 로고
    • Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis
    • Esposito M, Mazzotta A, Saraceno R, et al. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol 2009; 22: 219-25.
    • (2009) Int J Immunopathol Pharmacol , vol.22 , pp. 219-225
    • Esposito, M.1    Mazzotta, A.2    Saraceno, R.3
  • 6
    • 84892565281 scopus 로고    scopus 로고
    • Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: A multicentre, cross-sectional study
    • doi: 10.1111/jdv.12066. [Epub ahead of print]
    • Mahé E, Reguiai Z, Barthelemy H, et al. Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study. J Eur Acad Dermatol Venereol 2012; doi: 10.1111/jdv.12066. [Epub ahead of print].
    • (2012) J Eur Acad Dermatol Venereol
    • Mahé, E.1    Reguiai, Z.2    Barthelemy, H.3
  • 7
    • 84855912765 scopus 로고    scopus 로고
    • -174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers
    • Di RenzoL, Bianchi A, Saraceno R, et al. -174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers. Pharmacogenet Genomics 2012; 22: 134-42.
    • (2012) Pharmacogenet Genomics , vol.22 , pp. 134-142
    • Di, R.1    Bianchi, A.2    Saraceno, R.3
  • 8
    • 80052710308 scopus 로고    scopus 로고
    • Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment
    • Di RenzoL, Saraceno R, Schipani C, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. Dermatol Ther 2011; 24: 446-51.
    • (2011) Dermatol Ther , vol.24 , pp. 446-451
    • Di, R.1    Saraceno, R.2    Schipani, C.3
  • 9
    • 84868378962 scopus 로고    scopus 로고
    • Variation pondérale chez les patients recevant un traitement systémique pour un psoriasis
    • Forien M, Mahé E, Sin C, et al. Variation pondérale chez les patients recevant un traitement systémique pour un psoriasis. Ann Dermatol Venereol 2012; 139: 649-51.
    • (2012) Ann Dermatol Venereol , vol.139 , pp. 649-651
    • Forien, M.1    Mahé, E.2    Sin, C.3
  • 10
    • 22244433242 scopus 로고    scopus 로고
    • Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment
    • Briot K, Garnero P, Le Henanff A, et al. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment. Ann Rheum Dis 2005; 64: 1137-40.
    • (2005) Ann Rheum Dis , vol.64 , pp. 1137-1140
    • Briot, K.1    Garnero, P.2    Le Henanff, A.3
  • 11
    • 44349177615 scopus 로고    scopus 로고
    • Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment
    • Briot K, Gossec L, Kolta S, et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2008; 35: 855-61.
    • (2008) J Rheumatol , vol.35 , pp. 855-861
    • Briot, K.1    Gossec, L.2    Kolta, S.3
  • 12
    • 33845491244 scopus 로고    scopus 로고
    • Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis
    • Marcora SM, Chester KR, Mittal G, et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006; 84: 1463-72.
    • (2006) Am J Clin Nutr , vol.84 , pp. 1463-1472
    • Marcora, S.M.1    Chester, K.R.2    Mittal, G.3
  • 13
    • 77955458413 scopus 로고    scopus 로고
    • Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis
    • Alcorn N, Tierney A, Wu O, et al. Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1571.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1571
    • Alcorn, N.1    Tierney, A.2    Wu, O.3
  • 14
    • 21244432426 scopus 로고    scopus 로고
    • Impact of infliximab on serum leptin level in patients with Crohn's disease
    • Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin level in patients with Crohn's disease. J Clin Endocrinol Metab 2005; 90: 3510-16.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 3510-3516
    • Franchimont, D.1    Roland, S.2    Gustot, T.3
  • 15
    • 84863836287 scopus 로고    scopus 로고
    • Counteracting inflammation: A promising therapy in cachexia
    • Argiles JM, Lopez-Soriano FJ, Busquets S,. Counteracting inflammation: a promising therapy in cachexia. Crit Rev Oncog 2012; 17: 253-62.
    • (2012) Crit Rev Oncog , vol.17 , pp. 253-262
    • Argiles, J.M.1    Lopez-Soriano, F.J.2    Busquets, S.3
  • 16
    • 84873180906 scopus 로고    scopus 로고
    • Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-α in patients with inflammatory rheumatic disorders: A 16-week comparative study
    • Younis S, Rosner I, Rimar D, et al. Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-α in patients with inflammatory rheumatic disorders: a 16-week comparative study. Cytokine 2013; 61: 353-5.
    • (2013) Cytokine , vol.61 , pp. 353-355
    • Younis, S.1    Rosner, I.2    Rimar, D.3
  • 17
    • 77953509678 scopus 로고    scopus 로고
    • Adipose tissue, inflammation and atherosclerosis
    • Gustafson B,. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010; 17: 332-41.
    • (2010) J Atheroscler Thromb , vol.17 , pp. 332-341
    • Gustafson, B.1
  • 18
    • 84879117065 scopus 로고    scopus 로고
    • A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients
    • doi: 10.1111/j.1468-3083.2012.04611.x. [Epub ahead of print]
    • Park KK, Wu JJ, Koo J,. A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. J Eur Acad Dermatol Venereol 2012; doi: 10.1111/j.1468-3083.2012.04611.x. [Epub ahead of print].
    • (2012) J Eur Acad Dermatol Venereol
    • Park, K.K.1    Wu, J.J.2    Koo, J.3
  • 19
    • 80051703774 scopus 로고    scopus 로고
    • Obesity and psoriasis: Body weight and body mass index influence the response to biological treatment
    • Puig L,. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011; 25: 1007-11.
    • (2011) J Eur Acad Dermatol Venereol , vol.25 , pp. 1007-1011
    • Puig, L.1
  • 20
    • 77955924889 scopus 로고    scopus 로고
    • Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis
    • Menter A, Gordon K, Leonardi C, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010; 63: 448-56.
    • (2010) J Am Acad Dermatol , vol.63 , pp. 448-456
    • Menter, A.1    Gordon, K.2    Leonardi, C.3
  • 21
    • 84876956361 scopus 로고    scopus 로고
    • Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: Subanalysis of the BELIEVE study
    • Paul C, van de Kerkhof P, Puig L, et al. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. Eur J Dermatol 2012; 22: 762-9.
    • (2012) Eur J Dermatol , vol.22 , pp. 762-769
    • Paul, C.1    Van De Kerkhof, P.2    Puig, L.3
  • 22
    • 80051681379 scopus 로고    scopus 로고
    • Consistency of infliximab response across subgroups of patients with psoriasis: Integrated results from randomized controlled clinical trials
    • Reich K, Menter A, Plotnick M, et al. Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized controlled clinical trials. Psoriasis Forum 2007; 13: 21-6.
    • (2007) Psoriasis Forum , vol.13 , pp. 21-26
    • Reich, K.1    Menter, A.2    Plotnick, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.